No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GLYC240517P4000
- 2.40
- 0.000.00%
15min DelayClose Apr 15 15:34 ET
0.00High0.00Low
0.00Open2.40Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover0.00%IV466.77%PremiumMay 17, 2024Expiry Date3.72Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
GlycoMimetics GAAP EPS of -$0.17 In-line
GlycoMimetics | 10-Q: Quarterly report
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50
Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50.
Express News | GlycoMimetics Inc : Jefferies Cuts Target Price to $1 From $3
GlycoMimetics Announces Promising Phase 3 Leukemia Drug Results
Comments
$GlycoMimetics(GLYC.US$ watching, but not seeing the value case to actually enter even at reduced price
1
1
$GlycoMimetics(GLYC.US$ sad stuff.. I'm glad i wasnt to invested but i feel bad for people that were. This is the beauty of bio stocks. either goes up 80% or jumps head first off a cliff lol
1
$GlycoMimetics(GLYC.US$ Reuters· 1 min ago
GlycoMimetics Inc: Study of Uproleselan Combined With Chemotherapy Did Not Meet Its Primary Endpoint
GlycoMimetics Inc - Nci Phase 2/3 Study of Uproleselan in Aml Continues
GlycoMimetics Inc: Study of Uproleselan Combined With Chemotherapy Did Not Meet Its Primary Endpoint
GlycoMimetics Inc - Nci Phase 2/3 Study of Uproleselan in Aml Continues
2
4
Read more